Megakaryocyte progenitor (MkP)

Megakaryocyte progenitors are hematopoietic precursor cells committed to the megakaryocytic lineage responsible for generating mature megakaryocytes—the source of circulating platelets critical for hemostasis. These cells arise from multipotent hematopoietic stem cells through defined intermediate stages within the bone marrow hierarchy. Their identification relies on surface markers such as CD41+ within specific myeloid compartments. Proliferation and differentiation are tightly regulated by cytokines—primarily thrombopoietin acting via its receptor MPL—and downstream signaling cascades including JAK/STAT, MAPK, and PI3K/Akt pathways. Dysregulation leads to clinical disorders ranging from thrombocytopenia to myeloproliferative neoplasms characterized by increased numbers or abnormal function of these precursors. While they themselves are not direct drug targets, understanding their regulation enables therapeutic manipulation using agents that modulate upstream signals controlling their expansion and maturation.

Other names

Megakaryocytic progenitorMkPUnipotent megakaryocyte progenitorMegP

For drugs affecting this process: Activation of thrombopoietin receptor MPL stimulates JAK/STAT, MAPK, and PI3K/Akt pathways promoting survival and proliferation of megakaryocyte lineage cells. Inhibition of JAK2 blocks aberrant signaling in conditions like essential thrombocythemia/myelofibrosis with mutant JAK2 driving excessive MkP expansion.